Jack Fu1, An Ngo, Ki Shin, Eduardo Bruera. 1. Department of Palliative Care and Rehabilitation Medicine, The University of Texas M.D. Anderson Cancer Center , Houston, Texas.
Abstract
BACKGROUND: Injectable antispasticity agents have been utilized for the reduction of pain. However, there are no reports of its use for end-of-life pain. PATIENT CASE: A 62-year-old female with a history of progressive left frontotemporal glioblastoma status post gross total resection, radiation, and chemotherapy presented to the physical medicine and rehabilitation (PM&R) clinic for management of spastic quadriplegia and pain. At the time of presentation to the PM&R clinic she was no longer eligible for further cancer treatment. The patient had been declining neurologically with cognitive changes, weakness, and increasing spasticity. The patient had an Edmonton Symptom Assessment Scale (ESAS) pain score of 8/10 at her visit, as reported by her husband. She exhibited mild to moderate spasticity during the exam. Cognitively, she was unable to follow commands and would fluctuate between being awake for a few minutes and sleeping during the exam. She was not on any oral muscle relaxants and none were started due to her state of hypoarousal. Nine days after the initial consultation she received 700 units of onabotulinum toxin into her bilateral upper limbs and left thigh and a phenol nerve block to her left tibial nerve. At a follow-up visit 28 days later in the palliative care clinic, the ESAS pain score was 0. The patient died 51 days post-injection. CONCLUSION: The case report demonstrates the use of injectable antispasticity agents in the reduction of end-of-life pain in a glioblastoma patient.
BACKGROUND: Injectable antispasticity agents have been utilized for the reduction of pain. However, there are no reports of its use for end-of-life pain. PATIENT CASE: A 62-year-old female with a history of progressive left frontotemporal glioblastoma status post gross total resection, radiation, and chemotherapy presented to the physical medicine and rehabilitation (PM&R) clinic for management of spastic quadriplegia and pain. At the time of presentation to the PM&R clinic she was no longer eligible for further cancer treatment. The patient had been declining neurologically with cognitive changes, weakness, and increasing spasticity. The patient had an Edmonton Symptom Assessment Scale (ESAS) pain score of 8/10 at her visit, as reported by her husband. She exhibited mild to moderate spasticity during the exam. Cognitively, she was unable to follow commands and would fluctuate between being awake for a few minutes and sleeping during the exam. She was not on any oral muscle relaxants and none were started due to her state of hypoarousal. Nine days after the initial consultation she received 700 units of onabotulinum toxin into her bilateral upper limbs and left thigh and a phenol nerve block to her left tibial nerve. At a follow-up visit 28 days later in the palliative care clinic, the ESAS pain score was 0. The patient died 51 days post-injection. CONCLUSION: The case report demonstrates the use of injectable antispasticity agents in the reduction of end-of-life pain in a glioblastomapatient.
Authors: D M Simpson; J-M Gracies; H K Graham; J M Miyasaki; M Naumann; B Russman; L L Simpson; Y So Journal: Neurology Date: 2008-05-06 Impact factor: 9.910
Authors: Julie K Silver; Vishwa S Raj; Jack B Fu; Eric M Wisotzky; Sean Robinson Smith; Rebecca A Kirch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603